UPB · XBRL financial data
Upstream Bio financial statements, every fiscal year
The same tables from 2 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (UPB's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Revenue from contracts with customers | 2,370 | 2,854 |
| Research and development | 62,966 | 136,806 |
| General and administrative | 17,168 | 26,409 |
| Total operating expenses | 80,134 | 163,215 |
| Operating income (loss) | (77,764) | (160,361) |
| Interest income | 12,123 | 16,933 |
| Income tax expense (benefit) | 0 | 0 |
| Net income (loss) | (62,806) | (143,443) |
| Earnings per share, basic USD per share | (5.58) | (2.66) |
| Earnings per share, diluted USD per share | (5.58) | (2.66) |
| Weighted average shares, basic thousands of shares | 13,682 | 53,853 |
| Weighted average shares, diluted thousands of shares | 13,682 | 53,853 |
Balance sheet
CSVFiscal years (UPB's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 325,892 | 101,578 |
| Short-term investments | 144,559 | 239,931 |
| Accounts receivable | 613 | 668 |
| Prepaid and other current assets | 8,096 | 9,620 |
| Total current assets | 479,160 | 351,797 |
| Property and equipment, net | 582 | 559 |
| Right-of-use asset | 1,783 | 1,222 |
| Goodwill | 0 | — |
| Total assets | 481,719 | 353,772 |
| Accounts payable | 4,041 | 2,726 |
| Total current liabilities | 10,737 | 13,452 |
| Lease liability, non-current | 1,130 | 549 |
| Total liabilities | 11,867 | 14,001 |
| Accumulated deficit | (190,780) | (334,223) |
| Total stockholders' equity | 469,852 | 339,771 |
| Total liabilities and equity | 481,719 | 353,772 |
| Common shares outstanding (cover page) thousands of shares | 53,641 | 54,420 |
Cash flows
CSVFiscal years (UPB's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Net income (loss) | (62,806) | (143,443) |
| Stock-based compensation | 6,004 | 10,332 |
| Depreciation and amortization | 89 | 188 |
| Net cash from operating activities | (59,172) | (133,275) |
| Purchases of property and equipment | 511 | 165 |
| Net cash from investing activities | (59,485) | (93,480) |
| Net cash from financing activities | 418,910 | 2,441 |
| Net change in cash | 300,253 | (224,314) |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Upstream Bio | 79,397 | 773 | (35,621)* | 54.8M | 7.3 quarters | 10-QJun 30, 2026 |
| Arvinas | 88,000 | 500 | (10,400)* | 65.5M | 13.0 quarters | 10-QSep 30, 2026 |
| aTYR PHARMA | 13,140 | 0 | (9,511)* | 2.5M | 4.6 quarters | 10-QSep 30, 2026 |
| Arbutus Biopharma | 19,171 | 1,014 | (6,018)* | 197.8M | 15.4 quarters | 10-QJun 30, 2026 |
| Zevra Therapeutics | 122,148 | 37,756 | 10,047* | 59.5M | — | 10-QSep 30, 2026 |
| Theravance Biopharma | 219,766 | 20,731 | (6,965)* | 51.9M | 55.7 quarters | 10-QJun 30, 2026 |
| Myriad Genetics | 107,100 | 202,700 | (6,500)* | 95.9M | 10.5 quarters | 10-QSep 30, 2026 |
| Kura Oncology | 70,242 | 20,874 | (62,549)* | 89.0M | 8.3 quarters | 10-QJun 30, 2026 |
| KalVista Pharmaceuticals | 213,768 | 40,863 | (14,455) | 53.2M | 19.7 quarters | 10-QMar 31, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.